OSIVAX
PARIS 8, ILE-DE-FRANCE 75008
$59.94M
Total Contract Value
6 awards
First Award
Jul 25, 2025
Last Award
Nov 13, 2025
Business Size
other than small
CAGE Code
FBDR2
Top Industries (NAICS)
| NAICS Code | Obligations | Awards |
|---|---|---|
| 541714 | $20.23M | 3 |
Contract Awards
2 awards found
75A50125C00006
Department of Health and Human Services
$744K
Sep 19, 2025
OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PREPARE THE IND PACKAGE FOR OVX836+SQ ADJUVANT.
NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2025
75A50125C00008
Department of Health and Human Services
$19.49M
Jul 25, 2025
OSIVAX - CLINICAL PROOF OF CONCEPT OF OVX836, A SINGLE-SHOT BROADLY PROTECTIVE INFLUENZA A VACCINE FOR IMMEDIATE PROTECTION AGAINST EMERGING PANDEMIC STRAINS
NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2025
Business Details
- UEI
- M4YDKJJRJYC7
- CAGE Code
- FBDR2
- Address
- 4 RUE DE COPENHAGUE
PARIS 8, 75008
Parent Company
OSIVAX
Data Source
This profile is based on federal contract award data from USAspending.gov.
View on USAspending.gov